Literature DB >> 35974232

Impact of Textbook Oncologic Outcome Attainment on Survival After Gastrectomy: A Review of the National Cancer Database.

Megan A Cibulas1, Azalia Avila1, Ashwin M Mahendra2, Shenae K Samuels3, Christopher J Gannon4, Omar H Llaguna5.   

Abstract

BACKGROUND: Textbook oncologic outcome (TOO) is a composite outcome measure realized when all desired short-term quality metrics are met after an oncologic operation. This study examined the incidence and impact of achieving a TOO among patients undergoing resection of gastric adenocarcinoma.
METHODS: The 2004-2016 National Cancer Database was queried for patients who underwent curative gastrectomy. Textbook oncologic outcome was defined as having met five metrics: R0 resection, American Joint Committee on Cancer-compliant lymph node evaluation (n ≥ 15), no prolonged hospital stay (< 75th percentile by year), no 30-day readmission, and receipt of guideline-accordant systemic therapy.
RESULTS: Of 34,688 patients identified, 8249 (23.8 %) achieved TOO. The patients for whom TOO was achieved were more likely to have traveled farther (p < 0.001) and received care in an academic (p < 0.001) or very high case-volume facility (p < 0.001). The TOO group had a significanty higher median overall survival (OS) than the non-TOO group (80.5 vs 35.3 months; p < 0.001). The Kaplan-Meier curve showed that at 12 months, the survival probability estimate was 92 % for the TOO group versus 77 % for the non-TOO group. At 60 months (long-term survival), survival probability estimates remained higher for the TOO group (57 % vs 38 %). The results of the multivariate Cox regression model found that TOO attainment was significantly associated with a reduced risk of death (hazard ratio, 0.82; p < 0.001).
CONCLUSION: The TOO measure is associated with improved OS and reduced risk of death after gastrectomy for gastric adenocarcinoma. Unfortunately, in this study, TOO was obtained in only 23.8 % of cases.
© 2022. Society of Surgical Oncology.

Entities:  

Year:  2022        PMID: 35974232     DOI: 10.1245/s10434-022-12388-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   4.339


  10 in total

1.  Adherence with operative standards in the treatment of gastric cancer in the United States.

Authors:  Beiqun Zhao; Sarah L Blair; Matthew H G Katz; Andrew M Lowy; Kaitlyn J Kelly
Journal:  Gastric Cancer       Date:  2019-11-19       Impact factor: 7.370

2.  Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients.

Authors:  J J Bonenkamp; I Songun; J Hermans; M Sasako; K Welvaart; J T Plukker; P van Elk; H Obertop; D J Gouma; C W Taat
Journal:  Lancet       Date:  1995-03-25       Impact factor: 79.321

3.  Using textbook outcome as a measure of quality of care in oesophagogastric cancer surgery.

Authors:  R T van der Kaaij; M V de Rooij; F van Coevorden; F E M Voncken; P Snaebjornsson; H Boot; J W van Sandick
Journal:  Br J Surg       Date:  2018-02-21       Impact factor: 6.939

4.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

5.  A National Cohort Study Evaluating the Association Between Short-term Outcomes and Long-term Survival After Esophageal and Gastric Cancer Surgery.

Authors:  Leonie R van der Werf; Bas P L Wijnhoven; Laura F C Fransen; Johanna W van Sandick; Grard A P Nieuwenhuijzen; Linde A D Busweiler; Richard van Hillegersberg; Michel W J M Wouters; Misha D P Luyer; Mark I van Berge Henegouwen
Journal:  Ann Surg       Date:  2019-11       Impact factor: 12.969

6.  Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.

Authors:  Ilfet Songun; Hein Putter; Elma Meershoek-Klein Kranenbarg; Mitsuru Sasako; Cornelis J H van de Velde
Journal:  Lancet Oncol       Date:  2010-04-19       Impact factor: 41.316

7.  Does a Higher Cutoff Value of Lymph Node Retrieval Substantially Improve Survival in Patients With Advanced Gastric Cancer?-Time to Embrace a New Digit.

Authors:  Yu-Yin Liu; Wen-Liang Fang; Frank Wang; Jun-Te Hsu; Chun-Yi Tsai; Keng-Hao Liu; Chun-Nan Yeh; Tse-Ching Chen; Ren-Chin Wu; Cheng-Tang Chiu; Ta-Sen Yeh
Journal:  Oncologist       Date:  2016-10-27

8.  Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial.

Authors:  H H Hartgrink; C J H van de Velde; H Putter; J J Bonenkamp; E Klein Kranenbarg; I Songun; K Welvaart; J H J M van Krieken; S Meijer; J T M Plukker; P J van Elk; H Obertop; D J Gouma; J J B van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus; M Sasako
Journal:  J Clin Oncol       Date:  2004-04-13       Impact factor: 44.544

9.  Incidence and impact of Textbook Outcome among patients undergoing resection of pancreatic neuroendocrine tumors: Results of the US Neuroendocrine Tumor Study Group.

Authors:  Charlotte M Heidsma; Madison Hyer; Diamantis I Tsilimigras; Flavio Rocha; Daniel E Abbott; Ryan Fields; Paula M Smith; George A Poultsides; Clifford Cho; Shishir K Maithel; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2020-03-17       Impact factor: 3.454

10.  Survival benefit of greater number of lymph nodes dissection for advanced node-negative gastric cancer patients following radical gastrectomy.

Authors:  Hongyong He; Zhenbin Shen; Xuefei Wang; Jing Qin; Yihong Sun; Xinyu Qin
Journal:  Jpn J Clin Oncol       Date:  2015-10-23       Impact factor: 3.019

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.